Business Wire

CA-NANOTEMPER

6.5.2024 15:18:35 CEST | Business Wire | Press release

Share
NanoTemper Brings Spectral Shift Technology to the Protein Production Market With Andromeda X, Enabling Biopharma and CROs to Increase Efficiency of Expression Screening for Recombinant Protein Targets

NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein production market with the release of Andromeda X, an instrument that determines optimal expression alongside thermal stability of recombinant proteins in crude lysates. Andromeda X increases the efficiency of protein production teams at Biopharma and CROs, who now have the ability to optimize purification schemes for challenging, low-yield targets much faster, and with unprecedented insights on thermal stability during expression screening.

“At NanoTemper, our vision of creating a world where every disease is treatable starts here, in early drug development. Without high-quality drug targets or protein therapeutics, researchers cannot realize this vision. So, we’ve adapted our reliable and trusted optics systems to provide valuable insights for those working to express and purify these critical targets,” says Dr. Philipp Baaske, co-CEO of NanoTemper.

Dr. Amit Gupta, Head of Product Management at NanoTemper, adds, “Andromeda X incorporates our Spectral Shift optics, which are precision engineered to be sensitive enough to reveal expression levels and stability characterization from small batch crude lysates before teams commit to a purification scheme. Andromeda X gives expression insights in less time than traditional SDS-PAGE gels and provides additional information on the foldedness and functionality of the recombinant proteins.”

With Andromeda X, protein production teams can now hand over high-quality recombinant proteins faster and save themselves the trouble of re-screening or chasing unpromising leads by assessing the stability of proteins early on. Andromeda provides all of the valuable information needed to help them quickly and efficiently select for conditions that result in expression of quality proteins.

Visit nanotempertech.com/andromeda to find out more details.

About NanoTemper Technologies

At NanoTemper, our vision is to help create a world where every disease is treatable. For us, that starts by equipping scientists with reliable biophysical tools that bring them the clarity, confidence, and momentum they need to discover and develop future therapies, even difficult ones. Because the path to a disease-free world requires courage, big thinking, and collaboration, we’ll continue to create innovative products that meet the needs of our customers as they face new and difficult challenges.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240503533952/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Klarna Names Chris Koegel as Chief Financial Officer12.11.2026 14:30:00 CET | Press release

Klarna Group plc (NYSE: KLAR), the everyday finance network, has appointed Chris Koegel as Chief Financial Officer, effective 1 January 2027, subject to regulatory approval. The appointment has been approved and endorsed by the Klarna Group plc board. He will succeed Niclas Neglén, who will remain CFO until the end of 2026. Koegel joins from Robinhood Markets Inc. (NASDAQ: HOOD), where he is Vice President, Head of Corporate Finance and Investor Relations. He joined Robinhood in 2022 and has served on the Leadership Team through a period of significant growth; the company’s valuation has grown from less than $10bn and has exceeded $100bn during his tenure. Before Robinhood, he was Head of Investor Relations at LPL Financial LLC (NASDAQ: LPLA) from 2015 to 2022, after spending 13 years at Bain & Company. Koegel has a BA in Mathematics from Williams College, an MBA from Dartmouth College, and is based in the US in the Boston, MA area. “Chris’s experience as a Finance leader at a US-liste

SLB Selected by Vår Energi for Integrated Drilling Services Offshore Norway12.11.2026 13:50:00 CET | Press release

Four-year scope covers two offshore rigs on the Norwegian Continental Shelf Global energy technology company SLB (NYSE: SLB) today announced it has been selected by Vår Energi as its main integrated drilling services supplier for the Transocean Barents and Deepsea Bergen rigs on the Norwegian Continental Shelf. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111105994/en/ SLB (NYSE: SLB) has been selected by Vår Energi as its main integrated drilling services supplier for the Transocean Barents and Deepsea Bergen rigs on the Norwegian Continental Shelf. The selection covers an initial four-year period, with four additional one-year extension options that could extend the scope through 2034. Two harsh-environment semisubmersibles will continuously drill exploration and development wells during this period. The integrated delivery model brings together technical expertise, digital workflows and operational execution across t

Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States12.11.2026 13:35:00 CET | Press release

Adults Living with NT1 Can Now be Prescribed ORZEYFUL, a New First-in-Class Orexin Medicine that Treats the Disease Holistically ORZEYFUL has the Potential to Redefine the Standard of Care by Targeting the Underlying Orexin Deficiency Associated with NT1 Takeda (TSE:4502/NYSE:TAK) announced that ORZEYFUL™ (oveporexton) CIV is now available in the U.S. by prescription for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults, bringing the first and only orexin agonist to this community. Learn more at ORZEYFUL.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111123458/en/ Orzeyful Logo “Living with narcolepsy type 1 is an ongoing struggle to keep it together – from scheduling naps and anticipating sleep attacks to figuring out how to be present as a mom and a professional,” said Emily P., clinical trial participant with NT1. “With ORZEYFUL, I feel more confident planning my day because my narcolep

MultiBank Group and Universal Sign Agreement to Develop USDU Settlement Capabilities for Institutional Clients12.11.2026 13:02:00 CET | Press release

MultiBank Group, one of the world’s largest financial derivatives institutions, has signed a memorandum of understanding (MoU) with Universal Digital Intl Limited (“Universal”) to develop settlement capabilities using USDU, Universal’s US dollar-backed stablecoin, for eligible institutional digital asset transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112192767/en/ MultiBank Group, one of the world’s largest financial derivatives institutions, has signed a memorandum of understanding (MoU) with Universal Digital Intl Limited (“Universal”) to develop settlement capabilities using USDU, Universal’s US dollar-backed stablecoin, for eligible institutional digital asset transactions. The initiative will begin with a pilot for eligible Professional Clients on mb.io, the Group’s cryptocurrency and digital asset trading platform. It combines MultiBank Group’s trading infrastructure, institutional relationships and li

IFF Launches CONCEPT MUSE, an AI-Powered Platform Designed to Accelerate Food and Beverage Product Development12.11.2026 13:00:00 CET | Press release

From inspiration to conceptualization, accelerated by technology and shaped by human expertise. IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences—today announced the launch of CONCEPT MUSE, a proprietary AI-powered tool for food and beverage concept generation. Drawing from IFF’s consumer insights, flavor expertise and market intelligence, CONCEPT MUSE helps identify market opportunities and uses simple prompts to generate differentiated concepts—complete with narratives, visual mockups and suggested technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111590865/en/ IFF's CONCEPT MUSE helps identify market opportunities and uses simple prompts to generate differentiated concepts. “Food and beverage innovation has always been a balance of art and science. Now digital transformation is adding a powerful new dimension to that equation,” said Benjamin Mattei, vice president of intellige

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye